Growing interest in CIK cell therapy highlights challenges. Creative Biolabs supports researchers with CAR-CIK ...

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101 ...

Blinded comparison of natural killer cell detection with AI-driven nanophotonic imaging versus traditional spectral flow cytometry: Development of the CB-Scout assay. This is an ASCO Meeting Abstract ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research ...

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...

A unique and reliable approach for inducing NK cells from iPSCs (iNK) in a completely feeder-free environment was designed in this study. After 35 days, the cell proportion of CD3-CD56 + iNK Cells ...

In a study that further corroborated these observations, scientists found that cyclic fasting in mice improved their antitumor responses mediated by natural killer (NK) cells. 4 The results, published ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to finish at $8.39 apiece, as investors took heart from the company’s optimism ...